Hints and tips:
Related Special Reports
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
...cancer drug developed by Hansoh Pharma....
...Pharma companies, while talking up pipelines, are turning to deals to boost their growth outlook....
...The company’s net profit increased 21.3 per cent to Rmb10.7bn, flattered by a favourable exchange rate....
...In the past year, Novo Nordisk has become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s most valuable pharma company, on the back of high demand...
...That doesn’t mean, as Lex argued, that the same old patent panics aren’t going to hurt the companies in the meantime. Take your medicine here....
...The company’s market cap has shrivelled to less than $10bn. Trouble can be traced back to 2016, when Teva acquired generics rival Actavis from Allergan for $40bn....
...The pharma group said drugs developed by its legacy companies helped to form the “building blocks” of today’s GSK....
...The company on Monday cut its 2023 revenue growth forecast to 10 per cent from 30 per cent and lowered guidance for 2024 and 2025....
...Impressive results also emerged for German pharma group Boehringer Ingelheim and Zealand Pharma’s survodutide....
...Contributions from the company’s acquisitions — notably the $43bn purchase of cancer biotechnology company Seagen — have yet to move the needle....
...Traditional healthcare companies are also striving to make headway in this space....
...As healthcare systems around the world put pressure on drug prices, pharma companies are also looking for ways to cut costs in research and development....
...But it is done when it is done,” he said on a media call after the company’s third-quarter earnings announcement....
...Pharma companies contribute 70 per cent of a slice of the costs below that. This component will be scrapped from 2025....
...The business has “the broadest and deepest pipeline of any [European] pharma company” said analysts at Barclays, with more than a dozen drugs reaching blockbuster status, with more than $1bn in sales in...
...Lex this week opined on three separate pharma outliers praying for rescues from their “lab rats” — as medical researchers sometimes call themselves....
...That would be another boost for the Danish company. But battered local drugmaker shares have even bigger upside potential....
...AstraZeneca has agreed to buy its first vaccine company in a deal worth up to $1.1bn, as the pharma group expands the infectious disease division it set up during the coronavirus pandemic....
...He said that the company’s “four challenges greatly limit our ability to choose our destiny: whether that be as a three-division company or in smaller parts”....
...The stock bucked the wider pharma sell-off, rising 60 per cent last year. A price to forward earnings multiple of over 50 values the stock more like a tech company than a pharma group....
...The biggest movers on European bourses on Monday morning include biotech group Zealand Pharma, distributor Bunzl, telecoms company Tele 2 and lender Bank of Ireland....
...Truckenmiller said the vaccine’s US launch should soothe concerns about the company’s broader pipeline of drugs....
...The drugs, developed by Japanese pharma company Eisai and US company Eli Lilly, tackle the build-up of amyloid plaques in the brain that trigger the disease, rather than address symptoms like current treatments...
International Edition